GT200500044A - MOLECULAR DISPERSIONS OF DROSPIRENONA - Google Patents

MOLECULAR DISPERSIONS OF DROSPIRENONA

Info

Publication number
GT200500044A
GT200500044A GT200500044A GT200500044A GT200500044A GT 200500044 A GT200500044 A GT 200500044A GT 200500044 A GT200500044 A GT 200500044A GT 200500044 A GT200500044 A GT 200500044A GT 200500044 A GT200500044 A GT 200500044A
Authority
GT
Guatemala
Prior art keywords
drospirenona
compositions
molecular dispersions
biodavailability
costable
Prior art date
Application number
GT200500044A
Other languages
Spanish (es)
Inventor
Adrian Funke
Torsten Wagner
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of GT200500044A publication Critical patent/GT200500044A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7007—Drug-containing films, membranes or sheets

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

UNA COMPOSICION FARMACEUTICA QUE COMPRENDE DROGAS ESTEROIDES, POR EJEMPLO PROGESTINA Y ESTROGENOS, EN FORMA MOLECULARMENTE DISPERSA. PREFERIBLEMENTE, LAS COMPOSICIONES SE PROVEEN COMO FORMAS SOLIDAS, SEMISOLIDAS O LIQUIDAS. DICHAS COMPOSICIONES TIENEN UNA ALTA BIODISPONIBILIDAD, BUENA ESTABILIDAD QUIMICA Y RAPIDA DISOLUCION POR LIBERACION IN VITRO Y SE PUEDEN PRODUCIR EN CONDICIONES QUE NO REQUIEREN EQUIPOS COSTOSOS NI RECAUDOS DE SEGURIDAD.A PHARMACEUTICAL COMPOSITION THAT INCLUDES STEROID DRUGS, BY PROGESTINE EXAMPLE AND STROGENS, MOLECULARLY DISPERSED. PREFERIBLY, THE COMPOSITIONS ARE PROVIDED AS SOLID, SEMISOLID OR LIQUID FORMS. THESE COMPOSITIONS HAVE HIGH BIODAVAILABILITY, GOOD CHEMICAL STABILITY AND FAST DISSOLUTION BY IN VITRO RELEASE AND CAN BE PRODUCED IN CONDITIONS THAT DO NOT REQUIRE COSTABLE EQUIPMENT OR SAFETY COLLECTION.

GT200500044A 2004-03-10 2005-03-10 MOLECULAR DISPERSIONS OF DROSPIRENONA GT200500044A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP04075713 2004-03-10

Publications (1)

Publication Number Publication Date
GT200500044A true GT200500044A (en) 2005-10-31

Family

ID=34928104

Family Applications (1)

Application Number Title Priority Date Filing Date
GT200500044A GT200500044A (en) 2004-03-10 2005-03-10 MOLECULAR DISPERSIONS OF DROSPIRENONA

Country Status (12)

Country Link
CN (1) CN1980636A (en)
AR (1) AR048002A1 (en)
DE (1) DE602005022952D1 (en)
GT (1) GT200500044A (en)
MY (1) MY143870A (en)
PA (1) PA8625901A1 (en)
PE (1) PE20060004A1 (en)
RS (1) RS50975B (en)
SV (1) SV2005002043A (en)
TW (2) TW200609000A (en)
UA (1) UA90263C2 (en)
UY (1) UY28802A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106109420B (en) * 2016-08-11 2018-07-06 吴启旸 Eplerenone solid dispersions and its preparation

Also Published As

Publication number Publication date
RS50975B (en) 2010-10-31
DE602005022952D1 (en) 2010-09-23
UY28802A1 (en) 2005-10-31
TW200840587A (en) 2008-10-16
TW200609000A (en) 2006-03-16
PA8625901A1 (en) 2006-07-03
MY143870A (en) 2011-07-15
AR048002A1 (en) 2006-03-15
SV2005002043A (en) 2005-11-04
CN1980636A (en) 2007-06-13
PE20060004A1 (en) 2006-02-16
UA90263C2 (en) 2010-04-26

Similar Documents

Publication Publication Date Title
BRPI0508612A (en) compositions comprising molecularly dispersed drospirenone
MA37809A1 (en) Biodegradable drug delivery for hydrophobic compositions
CL2007001724A1 (en) USE OF A STROGEN FOR THE TREATMENT OF DISEASES, CONDITIONS OR SYMPTOMS ASSOCIATED WITH DEFICIENT LEVELS OF STROGENS IN A WOMAN; PHARMACEUTICAL COMPOSITION THAT INCLUDES DAILY DOSAGE UNITS OF ESTRADIOL HEMIDRATE> 0.75 AND 1
CO6690737A2 (en) Stabilized chemical composition
CO6280466A2 (en) PHARMACEUTICAL DOSAGE FORM OF CONTROLLED RELEASE
GT200600097A (en) PHARMACEUTICAL FORMS WITH IMPROVED PHARMACOCINETIC PROPERTIES
CL2007002207A1 (en) COMPOUNDS DERIVED FROM SULFONYLAMINES; PHARMACEUTICAL COMPOSITION; AND USE OF COMPOUNDS IN THE TREATMENT OF GLAUCOMA.
WO2009074351A3 (en) Solid forms of tenofovir disoproxil
AR060784A1 (en) BINARY MIXING OF HIALURONIC ACID AND ITS THERAPEUTIC USE
UY37086A (en) MOLECULES THAT HAVE PESTICID USEFULNESS AND INTERMEDIATE PRODUCTS, COMPOSITIONS AND PROCESSES, RELATED TO THE SAME
TR201004346T2 (en) Pharmaceutical compositions for the treatment of depression and anxiety.
McGowan An overview of antiretroviral pre‐exposure prophylaxis of HIV infection
WO2008107611A3 (en) Dimethylsulfoxide formulation in mixture with additive for lowering the crystallization point of same, and applications of said mixture
AR064104A1 (en) DOSAGE FORMS IN VALSARTAN MICROEMULSION, AND METHODS TO PREPARE THEM
GT200500044A (en) MOLECULAR DISPERSIONS OF DROSPIRENONA
CL2012001085A1 (en) A gelatinized ready-to-eat product based on water, juice, and / or milk comprising at least two independent homogeneous gel masses, wherein the adjacent independent gel masses have different gel strengths.
Tailaiti et al. Urination Treatment Drug Oleanolic Acid Affects the Therapy Index of Zidovudine (AZT)
CO6382128A2 (en) TREATMENT OF VAGINAL ATROPHY IN WOMEN WITH RISK OF CARDIOVASCULAR PATHOLOGY
Cole Pre-degree pilot has its uses… and its limitations
Setswe Review, update and definition of indicators to monitor the social impacts and other aspects of HIV and AIDS in South Africa
郑映雪 The Connotations of Non-linguistic Signs in Communication
Chung et al. Study on Embryo-Fetal Development to Artesunate in Rats
TH93875B (en) Slow-acting mixtures Which contains octriotides and polylactide-co-glycolides. Two or more polymers
TH95064A (en) Pharmaceutical formulations
DOP2003000689A (en) PHARMACEUTICAL COMPOSITIONS OF SEMIORDENED AND POLYMER DRUGS